JP2022509257A5 - - Google Patents
Info
- Publication number
- JP2022509257A5 JP2022509257A5 JP2021530883A JP2021530883A JP2022509257A5 JP 2022509257 A5 JP2022509257 A5 JP 2022509257A5 JP 2021530883 A JP2021530883 A JP 2021530883A JP 2021530883 A JP2021530883 A JP 2021530883A JP 2022509257 A5 JP2022509257 A5 JP 2022509257A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- combination according
- composition according
- compound
- venetoclax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773686P | 2018-11-30 | 2018-11-30 | |
| US62/773,686 | 2018-11-30 | ||
| PCT/US2019/063993 WO2020113216A1 (en) | 2018-11-30 | 2019-12-02 | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509257A JP2022509257A (ja) | 2022-01-20 |
| JP2022509257A5 true JP2022509257A5 (https=) | 2022-12-14 |
Family
ID=70849819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530883A Pending JP2022509257A (ja) | 2018-11-30 | 2019-12-02 | ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200171001A1 (https=) |
| EP (1) | EP3886840A4 (https=) |
| JP (1) | JP2022509257A (https=) |
| KR (1) | KR20210150353A (https=) |
| CN (1) | CN113365622A (https=) |
| AU (1) | AU2019387508A1 (https=) |
| CA (1) | CA3133376A1 (https=) |
| WO (1) | WO2020113216A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PY2125608A (es) * | 2020-04-01 | 2021-12-28 | Fmc Corp | Atropisómeros de derivados de piridazinona como herbicidas |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| DK2940014T3 (en) * | 2012-12-28 | 2018-12-10 | Crystalgenomics Inc | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| EP2971079A1 (en) * | 2013-03-12 | 2016-01-20 | Novartis AG | Markers for isocitrate dehydrogenase inhibitors |
| EP2983670A4 (en) * | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| HK1255939A1 (zh) * | 2015-08-03 | 2019-09-06 | Gilead Sciences, Inc. | 用於治疗癌症之组合疗法 |
| ES2905915T3 (es) * | 2015-12-04 | 2022-04-12 | Servier Lab | Procedimientos de tratamiento de neoplasias malignas |
| JP6961879B2 (ja) * | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| CA3029851A1 (en) * | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
| WO2018081830A1 (en) * | 2016-10-31 | 2018-05-03 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
| TWI821174B (zh) * | 2017-02-21 | 2023-11-11 | 加拿大商艾普托斯生物科學公司 | 治療血液惡性腫瘤患者的方法 |
-
2019
- 2019-12-02 WO PCT/US2019/063993 patent/WO2020113216A1/en not_active Ceased
- 2019-12-02 US US16/700,426 patent/US20200171001A1/en not_active Abandoned
- 2019-12-02 EP EP19888779.6A patent/EP3886840A4/en not_active Withdrawn
- 2019-12-02 AU AU2019387508A patent/AU2019387508A1/en not_active Abandoned
- 2019-12-02 KR KR1020217019708A patent/KR20210150353A/ko not_active Ceased
- 2019-12-02 CN CN201980090539.1A patent/CN113365622A/zh active Pending
- 2019-12-02 CA CA3133376A patent/CA3133376A1/en active Pending
- 2019-12-02 JP JP2021530883A patent/JP2022509257A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lü et al. | Homoharringtonine and omacetaxine for myeloid hematological malignancies | |
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2024507938A5 (https=) | ||
| JP2011503063A5 (https=) | ||
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| JP2020535173A5 (https=) | ||
| JP2020505433A5 (https=) | ||
| JP2023508496A5 (https=) | ||
| JP2020117553A5 (https=) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2024542984A5 (https=) | ||
| CN113908159A (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Song et al. | Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study | |
| JP2021522246A5 (https=) | ||
| JP2021522246A (ja) | 癌治療のための併用 | |
| JP7489397B2 (ja) | Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 | |
| JP2022509257A5 (https=) | ||
| JP2023505301A5 (https=) | ||
| Sangwan et al. | Imatinib analogs in chronic myeloid leukemia: a systematic qualitative review | |
| WO2021160147A1 (zh) | 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途 | |
| Barber et al. | Hematologic toxicities of small molecule tyrosine kinase inhibitors | |
| Jäger et al. | Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment |